Literature DB >> 29714540

Evaluation and Characterization of Health Economics and Outcomes Research in SAARC Nations.

Manthan Mehta1, Rajan Nerurkar1.   

Abstract

OBJECTIVE: To identify, evaluate, and characterize the variety, quality, and intent of the health economics and outcomes research studies being conducted in SAARC (South Asian Association for Regional Cooperation) nations.
METHODS: Studies published in English language between 1990 and 2015 were retrieved from Medline databases using relevant search strategies. Studies were independently reviewed as per Cochrane methodology and information on the type of research and outcomes were extracted. Quality of reporting was assessed.
RESULTS: Of the 2638 studies screened from eight SAARC nations, a total of 179 were included for review (India = 140; Bangladesh = 12; Sri Lanka = 8; Pakistan = 7; Afghanistan = 5; Nepal = 4; Bhutan = 2; Maldives = 1). The broad study categories were cost-effectiveness analyses (CEAs = 76 studies), cost analyses (35 studies), and burden of illness (BOI=26 studies). The outcomes evaluated were direct costs, indirect costs, and incremental cost-effectiveness ratio (ICER), quality-adjusted life-years (QALYs), and disability-adjusted life-years (DALYs). Cost of medicines, consultation and hospital charges, and monitoring costs were assessed as direct medical costs along with non-direct medical costs such as travel and food for patients and caregivers. The components of indirect costs were loss of income of patients and caregivers and loss of productivity. Quality of life (QoL) was assessed in 48 studies. The most commonly used instrument for assessing QoL was the WHO-Quality of Life BREF (WHOQOL-BREF) questionnaire (76%). The Quality of Health Economic Studies (QHES) score was used for quality assessment of full economic studies (44 studies). The mean QHES score was 43.76.
CONCLUSION: This review identifies various patterns of health economic studies in eight SAARC nations. The quality of economic evaluation studies for health care in India, Bangladesh, Sri Lanka, Pakistan, Afghanistan, Nepal, Bhutan, and Maldives needs improvement. There is a need to generate the capacity of researchers to undertake quality economic evaluations as well as an orientation of the policy makers so that there is a demand for such studies as well as a scope for its use in policy making.

Entities:  

Keywords:  HEOR; India; cost analysis; pharmacoeconomics

Mesh:

Year:  2017        PMID: 29714540     DOI: 10.1177/2168479017731583

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  3 in total

1.  The Health Economic Impact of Nephrotic Syndrome in the United States.

Authors:  Christine A Simon; Eloise Salmon; Hailey E Desmond; Susan F Massengill; Wilson P Gipson; Debbie S Gipson
Journal:  Kidney360       Date:  2022-04-25

Review 2.  Challenge of post-COVID era: management of cardiovascular complications in asymptomatic carriers of SARS-CoV-2.

Authors:  Shreyasi Gupta; Arkadeep Mitra
Journal:  Heart Fail Rev       Date:  2021-01-11       Impact factor: 4.214

3.  A retrospective cross-sectional descriptive study to critically appraise the quality of reporting of health economic evaluations conducted in the Indian setting.

Authors:  Sandeep Kumar Gupta; Ravi Kant Tiwari; Raj Kumar Goel
Journal:  Perspect Clin Res       Date:  2021-01-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.